Pfizer: Amidst the global COVID-19 pandemic, a common dilemma that has caused worries among most is that of ‘which vaccine to take?’ and ‘which vaccine is more effective on the Indian Strain of the virus?’
According to the studies conducted by the UK government, it has been found that either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective on the B.1.617 Indian double mutant strain of COVID-19.
The Serum Institute of India is producing the Oxford/AstraZeneca two-dose vaccine as Covishield. The same is being made available among the adult population in India.
The findings from the study are reportedly based on data from Public Health England (PHE). The said study revealed that both the doses are over 87 per cent effective on the B.117 variant which was first discovered in England and was claimed to be highly transmissible.
In an article by The Telegraph, the latest study’s findings were presented to a meeting of the government’s New and Emerging Respiratory Virus Threats Advisory Group (Nervtag) this week.
The Public Health England statistics, conducted recently, suggest that case numbers of the B1.617.2 variant had risen by over 2000 new cases over the past week, hitting a total of 3,424 cases across the country.
Director of COVID-19 genomics at the Sanger Institute Dr Jeffrey Barrett said to the BBC, “I think it’s clearly growing, which anyone can see from the numbers as they are reported week by week.”
The Indian Union Health Ministry commented on the alarming rate on May 22, Saturday. In the same, they informed about a reduction of COVID-19 death and cases all over the country. However, these six states including Maharashtra, Karnataka, Tamil Nadu, UP, Punjab and Delhi.
Though there is a reported overall decline in case burden, the Covid-19 positivity rate is still over 10% in 382 districts.
We request you to support our award-winning journalism by making a financial contribution towards our efforts. Your funds will ensure we can continue to bring you amazing stories of women, and the impact they are making and spotlight half the country's population because they deserve it.
By proceeding, you are agreeing to our Terms of Service .View our FAQs and Support page .